Skip directly to content


NimenrixTM (護腦苗) 為腦膜炎雙球菌4價結合疫苗,針對血清型A、C、W135及Y。6星期大的初生嬰兒已可接種,1歲或以上只需1針,並無年齡上限,可獲得長效保護1-5。護腦苗是香港唯一獲歐洲藥物管理局及香港衛生署核准出售的供初生嬰兒接種的腦膜炎雙球菌4價結合疫苗6-7,更於全球超過60個國家及地區註冊8,獲得廣泛認可。而且如曾接種腦膜炎雙球菌多醣疫苗,亦可作為加強劑使用1。保護你的摯愛,立即行動!


  1. NimenrixTM (Meningococcal group A, C, W-135 and Y conjugate vaccine) Prescribing Information. Pfizer Corporation Hong Kong Limited: December 2016.
  2. Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Human vaccines & immunotherapeutics. 2016 Jan 2;12(1):132-9.
  3. Lee CJ, Lee LH, Koizumi K. Polysaccharide vaccines for prevention of encapsulated bacterial infections: part 1. Infections in medicine. 2002;19(3):127-33.
  4. Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. The Pediatric infectious disease journal. 2015 Nov 1;34(11):1236-43.
  5. Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. BMC infectious diseases. 2015 Dec;15(1):409.
  6. European Medicines Agency.  Nimenrix. Available at Accessed 19 June 2019.
  7. Drug Office, Department of Health. Search Drugs Database: Nimenrix Vaccine. Available at Accessed 24 June 2019.
  8. Data on file – Global Regulatory System: Worldwide Registration Status of Nimenrix. Pfizer Inc.
[PP-CPF-HKG-0065] SEP2019